Victoria Villaflor - Concepedia

Author

Victoria Villaflor

Also Known As

Liao, C.-Y., O'Brien, Mary, V. M. Villaflor, V. Meucci Villaflor, V. Villaflor, V.M. Villaflor, Victoria M Villaflor, Victoria M. Villaflor, Victoria Meucci Villaflor, Victoria Villaflor

242

Publications

4.8K

Citations

H-Index

Concepts

All Affiliations

University of Chicago Northwestern University City of Hope Memorial Sloan Kettering Cancer Center Duke Medical Center

About

Victoria Villaflor is an author at University of Chicago specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	28	1.3K
2	Pathology	14	16	770
3	Health Sciences	12	13	709
4	Immunology	8	8	344
5	Cell Biology	2	2	104

Victoria Villaflor

Publications

3.6K

Citations

H-Index

Page 1

	Year	Citations
Phase III Randomized Trial of Induction Chemotherapy in Patients With N2 or N3 Locally Advanced Head and Neck Cancer Ezra E.W. Cohen, Theodore Karrison, Masha Kocherginsky, Journal of Clinical Oncology	2014	558
Stereotactic body radiotherapy for multisite extracranial oligometastases Joseph K. Salama, Michael D. Hasselle, Steven J. Chmura, Cancer	2011	321
OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer Tanguy Y. Seiwert, Corey C. Foster, Elizabeth A. Blair, Annals of Oncology	2018	220
Phase 2 study of sunitinib in refractory thyroid cancer Ezra E.W. Cohen, Burton Needles, K. J. Cullen, Journal of Clinical Oncology Thyroid CancersSurgical OncologyPathologyMtc PatientsTumor Biology	2008	148
DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). Ezra E.W. Cohen, Theodore Karrison, Masha Kocherginsky, Journal of Clinical Oncology Squamous Cell CarcinomaSame CrtPathologyTreatment VerificationRadiation Medicine	2012	135
Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti–PD-1/PD-L1 Therapy in Non–Small-Cell Lung Cancer Young Kwang Chae, Andrew A. Davis, Kirtee Raparia, Clinical Lung Cancer Genome InstabilityTumor Mutational BurdenMedicineImmunologyPathology	2018	132
Prevalence of Off-Label Use and Spending in 2010 Among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical Oncologists Rena M. Conti, Arielle Bernstein, Victoria Villaflor, Journal of Clinical Oncology	2013	124
Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer Young Kwang Chae, Andrew A. Davis, Sarita Agte, The Oncologist	2019	121
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma Toni M. Brand, Mari Iida, Andrew P. Stein, Clinical Cancer Research	2015	117
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers Peter C. Enzinger, Barbara Burtness, Donna Niedzwiecki, Journal of Clinical Oncology	2016	117

Page 1